March/April 2013

With the approval of biosimilars in the United States, a key safety issue is the naming configuration. This article discusses the issues and options around biosimilar naming.

A new documentary has been released that underscores the need for accelerating alternative pathways for new discoveries that hold the promise for curing patients.

The pharmacist and retail pharmacy will play an expanding role in the triple aim solution of access, quality, and cost.

Generic atorvastatin led to an increase in generic dispensing rate and a reduction in the cost of treatment for patients requiring cholesterol-lowering treatment. The upcoming introduction of the PCSK9 inhibitor may change this trend.

Total cost of care for patients whose glycated hemoglobin levels were

Suboptimal adherence to hormone therapy was associated with higher medical costs, but optimal adherence was not associated with total cost savings across a 4-year period.